NO Venture Capitalists Invested in Arcturus' Self-Amplifying mRNA. Here's Why
sa-mRNA is part of the flagship US government funded dual-use mRNA lipid nanoparticle technology portfolio used to create bioweapons ranging from SARS-CoV-2 to H15N1 to 'vaccines.'
June 2, 2025: When Arcturus announced, “that the FDA has granted Fast Track Designation for the self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, designed for active immunization to protect against disease caused by influenza A H5N1,”on April 10,2025, many MAHA influencers responded in sharp criticism of the FDA fast-tracking saRNA technology.
Keep reading with a 7-day free trial
Subscribe to The Kingston Report to keep reading this post and get 7 days of free access to the full post archives.